ProShares Ultra Nasdaq Biotechnology (BIB)
NASDAQ: BIB · Real-Time Price · USD
115.41
+0.99 (0.87%)
Sep 28, 2026, 1:33 PM EDT - Market open
| Assets | $95.94M |
| Expense Ratio | 0.95% |
| PE Ratio | n/a |
| Shares Out | 840,000 |
| Dividend (ttm) | $0.22 |
| Dividend Yield | 0.19% |
| Ex-Dividend Date | Sep 23, 2026 |
| Payout Frequency | Semi-Annual |
| Payout Ratio | n/a |
| Volume | 3,522 |
| Open | 113.18 |
| Previous Close | 114.42 |
| Day's Range | 112.94 - 116.53 |
| 52-Week Low | 57.37 |
| 52-Week High | 126.40 |
| Beta | 1.22 |
| Holdings | 255 |
| Inception Date | Apr 8, 2010 |
About BIB
Fund Home PageThe ProShares Ultra Nasdaq Biotechnology (BIB) is an exchange-traded fund that is based on the NASDAQ / Biotechnology index. The fund provides 2x daily exposure to a modified market-cap-weighted index of biotechnology and pharmaceutical companies listed on NASDAQ. BIB was launched on Apr 8, 2010 and is issued by ProShares.
Asset Class Equity
Category Trading--Leveraged Equity
Stock Exchange NASDAQ
Ticker Symbol BIB
ETF Provider ProShares
Index Tracked NASDAQ / Biotechnology
Top 10 Holdings
163.05% of assets| Name | Symbol | Weight |
|---|---|---|
| NASDAQ BIOTECHNOLOGY INDEX SWAP CITIBANK NA | n/a | 38.38% |
| NASDAQ BIOTECHNOLOGY INDEX SWAP BANK OF AMERICA NA | n/a | 36.79% |
| NASDAQ BIO INDEX SWAP BNP PARIBAS | n/a | 29.89% |
| NASDAQ BIOTECHNOLOGY INDEX SWAP GOLDMAN SACHS INTERNATIONAL | n/a | 19.47% |
| NASDAQ BIOTECHNOLOGY INDEX SWAP SOCIETE GENERALE | n/a | 18.54% |
| NASDAQ BIOTECHNOLOGY INDEX SWAP UBS AG | n/a | 4.64% |
| Gilead Sciences, Inc. | GILD | 4.38% |
| Vertex Pharmaceuticals Incorporated | VRTX | 4.10% |
| Amgen Inc. | AMGN | 4.09% |
| Regeneron Pharmaceuticals, Inc. | REGN | 2.77% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 23, 2026 | $0.08255 | Sep 29, 2026 |
| Mar 25, 2026 | $0.00714 | Mar 31, 2026 |
| Dec 24, 2025 | $0.13464 | Dec 31, 2025 |
| Sep 24, 2025 | $0.18054 | Sep 30, 2025 |
| Jun 25, 2025 | $0.17058 | Jul 1, 2025 |
| Mar 26, 2025 | $0.13094 | Apr 1, 2025 |
Performance
BIB had a total return of 98.52% in the past year, including dividends. Since the fund's inception, the average annual return has been 18.22%.
News
Here is a List of Small-Cap Biotech ETFs to Watch for Big Gains in 2026
Biotech ETFs are regaining attention as analyst targets signal renewed upside heading into 2026, particularly among small- and mid-cap drug developers. The ProShares Ultra Nasdaq Biotechnology ETF ($B...
7 months ago - TipRanks